Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of switching neoadjuvant chemotherapy to gemcitabine + cisplatin after poor response to TAC in locally advanced breast cancer
ChiCTR1900021887Phase 3Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Mar 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin, vinorelbine, docetaxel, doxorubicin and 1 more in breast cancer (3 arms), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoint: Pathological complete response. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
gemcitabinecisplatinvinorelbinedocetaxeldoxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900021887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021887.